首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1567911篇
  免费   108013篇
  国内免费   2576篇
耳鼻咽喉   23017篇
儿科学   51697篇
妇产科学   45222篇
基础医学   229695篇
口腔科学   43738篇
临床医学   131054篇
内科学   307846篇
皮肤病学   35391篇
神经病学   127311篇
特种医学   62137篇
外国民族医学   415篇
外科学   241492篇
综合类   28168篇
现状与发展   1篇
一般理论   388篇
预防医学   111481篇
眼科学   35617篇
药学   117894篇
  1篇
中国医学   3162篇
肿瘤学   82773篇
  2019年   12098篇
  2018年   18306篇
  2017年   13824篇
  2016年   16154篇
  2015年   17704篇
  2014年   23319篇
  2013年   35433篇
  2012年   49423篇
  2011年   52163篇
  2010年   30621篇
  2009年   27876篇
  2008年   50299篇
  2007年   54152篇
  2006年   54512篇
  2005年   53746篇
  2004年   51349篇
  2003年   50215篇
  2002年   49256篇
  2001年   67610篇
  2000年   70056篇
  1999年   58476篇
  1998年   16980篇
  1997年   15054篇
  1996年   14820篇
  1995年   13836篇
  1994年   13111篇
  1993年   12160篇
  1992年   43998篇
  1991年   43277篇
  1990年   42685篇
  1989年   41243篇
  1988年   38337篇
  1987年   37583篇
  1986年   35751篇
  1985年   34268篇
  1984年   25614篇
  1983年   22255篇
  1982年   13498篇
  1979年   24250篇
  1978年   17126篇
  1977年   14867篇
  1976年   13978篇
  1975年   15514篇
  1974年   18072篇
  1973年   17365篇
  1972年   16504篇
  1971年   15371篇
  1970年   14276篇
  1969年   13720篇
  1968年   12936篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
2.
3.
4.
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered.  相似文献   
5.
6.
7.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
8.
9.
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to...  相似文献   
10.
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号